CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364(11):1046-60; PMID:21410373; http://dx.doi.org/10.1056/NEJMra1011442.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28(5):1122-8; PMID:24157580; http://dx.doi.org/10.1038/leu.2013.313.
   PubMed Web of Science ®Google Scholar
• Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012; 26(12):2530-7; PMID:22733078; http://dx.doi.org/10.1038/leu.2012.140.
   PubMed Web of Science ®Google Scholar
• Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M, Harrington H, Doolittle H, Terpos E, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2013; 121(2):318-28; PMID:23169779; http://dx.doi.org/10.1182/blood-2012-06-436220.
   PubMed Web of Science ®Google Scholar
• Matsui W, Borrello I, Mitsiades C. Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant 2012; 18(1 Suppl):S27-32; PMID:22226109; http://dx.doi.org/10.1016/j.bbmt.2011.10.036.
   PubMedGoogle Scholar
• Van Valckenborgh E, Matsui W, Agarwal P, Lub S, Dehui X, De Bruyne E, Menu E, Empsen C, van Grunsven L, Agarwal J, et al. Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia 2012; 26(6):1436-9; PMID:22289925; http://dx.doi.org/10.1038/leu.2011.373.
   PubMed Web of Science ®Google Scholar
• Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28(12):2077-84; PMID:20308672; http://dx.doi.org/10.1200/JCO.2009.23.7172.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31(20):2540-7; PMID:23733781; http://dx.doi.org/10.1200/JCO.2012.46.2119.
   PubMed Web of Science ®Google Scholar
• Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112(10):4017-23; PMID:18669875; http://dx.doi.org/10.1182/blood-2008-05-159624.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia 2014; 29(3):689-95.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, et al. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica 2011; 96(10):1512-20; PMID:21606160; http://dx.doi.org/10.3324/haematol.2010.036814.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med 2014; 372(2):142-52.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014; 124(1):63-9; PMID:24855212; http://dx.doi.org/10.1182/blood-2014-03-563759.
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120(1):9-19; PMID:22498745; http://dx.doi.org/10.1182/blood-2012-02-408898.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, Casbourne D, Saxe D, Boise LH, Lonial S. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014; 28(3):690-3; PMID:24220275; http://dx.doi.org/10.1038/leu.2013.335.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371(10):895-905; PMID:25184862; http://dx.doi.org/10.1056/NEJMoa1402888.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012; 26(2):199-213; PMID:21852787; http://dx.doi.org/10.1038/leu.2011.214.
   PubMed Web of Science ®Google Scholar
• Ashjian E, Redic K. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. J Oncol Pharm Pract. 2015; 9:e92378.
   PubMedGoogle Scholar
• Paino T, Sarasquete ME, Paiva B, Krzeminski P, San-Segundo L, Corchete LA, Redondo A, Garayoa M, García-Sanz R, Gutiérrez NC, et al. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines. PLoS One 2014; 9(3):e92378; PMID:24658332; http://dx.doi.org/10.1371/journal.pone.0092378.
   PubMedGoogle Scholar
• Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol. 2003; 3(10):813-21; PMID:14523387; http://dx.doi.org/10.1038/nri1202.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Qi H, Lu KT, Dutta M, Gomez-Rodriguez J, Cheng J, Wakeland EK, Germain RN, Schwartzberg PL. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity 2010; 32(2):253-65; PMID:20153220; http://dx.doi.org/10.1016/j.immuni.2010.01.010.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14(9):2775-84; PMID:18451245; http://dx.doi.org/10.1158/1078-0432.CCR-07-4246.
   PubMed Web of Science ®Google Scholar
• Lee JK, Boles KS, Mathew PA. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol 2004; 34(10):2791-9; PMID:15368295; http://dx.doi.org/10.1002/eji.200424917.
   PubMed Web of Science ®Google Scholar
• De Salort J, Sintes J, Llinas L, Matesanz-Isabel J, Engel P. Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells. Immunol Lett 2011; 134(2):129-36; PMID:20933013; http://dx.doi.org/10.1016/j.imlet.2010.09.021.
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112(4):1329-37; PMID:17906076; http://dx.doi.org/10.1182/blood-2007-08-107292.
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 2013; 62(12):1841-9; PMID:24162108; http://dx.doi.org/10.1007/s00262-013-1493-8.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014; 28(4):917-27; PMID:24067492; http://dx.doi.org/10.1038/leu.2013.279.
   PubMed Web of Science ®Google Scholar
• Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine SM, et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res 2014; 20(15):3989-4000; PMID:24677374; http://dx.doi.org/10.1158/1078-0432.CCR-13-2510.
   PubMed Web of Science ®Google Scholar